Risk of tuberculosis and hepatitis B reactivation during adalimumab use in the treatment of hidradenitis suppurativa
Abstract Recently, adalimumab has become an important drug frequently used by dermatologists in the treatment of Hidradenitis suppurativa. While there are many publications by rheumatologists about the risk of hepatitis B and tuberculosis reactivation, the literature on reactivation in the treatment...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Portfolio
2025-09-01
|
| Serie: | Scientific Reports |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1038/s41598-025-95096-6 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|